The recurrence of hepatitis C in HCV-infected, orthotopic liver transplant recipients is a major problem that can influence the survival of both grafted tissue and patients. Yet the effects of immunosuppression strategies, in particular those of steroids, on disease recurrence remain unclear.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Forman, L. M. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122, 889–896 (2002).
Berenguer, M. et al. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13, 21–29 (2007).
Lake, J. R. Immunosuppression and outcomes of patients transplanted for hepatitis C. J. Hepatol. 44, 627–629 (2006).
Berenguer, M. et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 44, 717–722 (2006).
Roche, B. et al. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral Hepat. 14 (Suppl. 1), 89–96 (2007).
Lerut, J. et al. Minimization of steroids in liver transplantation. Transpl. Int. 22, 2–19 (2009).
Lladó, L. et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl. 14, 1752–1760 (2008).
Klintmalm, G. B. et al. corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl. 13, 1521–1531 (2007).
Klintmalm, G. B. et al. Hepatitis C (HCV)-3 study: severe HCV recurrence post liver transplantation (OLT) is decreased in patients treated with mycophenolate mofetil, particularly, in the absence of steroids. Hepatology 48 (Suppl. 4), 338A (2008).
Segev, D. L. et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 14, 512–525 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Roche, B., Samuel, D. Steroid use in HCV-infected liver transplant recipients. Nat Rev Gastroenterol Hepatol 6, 198–200 (2009). https://doi.org/10.1038/nrgastro.2009.38
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.38